"In most industrialized countries the balance appears to be shifting even further toward cost containment and away from recognition of the value of innovative medicines. Despite initiatives such as the EU's Pharmaceutical Forum to address this imbalance, national policies in Europe, North America and elsewhere appear on a trend toward greater price controls and restrictions on access to new therapies, especially biopharmaceuticals. Industrialized countries throughout the world are sharing their practices and many use assessments by other countries to help justify their own restrictive decisions."

Objective1:Discuss how biopharmaceutical companies can address the challenge of pricing in a global market.

Objective2:Outline the trends in national and regional policies governing pricing and reimbursement for the innovative sector.

Objective3:"Explore what measures the industry can take to demonstrate the value of innovation to governments.